Arvinas First Quarter 2025 Earnings: Beats Expectations

Arvinas (NASDAQ:ARVN) First Quarter 2025 Results

Key Financial Results

• Revenue: US$188.8m (up by US$163.5m from 1Q 2024).
• Net income: US$82.9m (up from US$69.4m loss in 1Q 2024).
• Profit margin: 44% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue.
• EPS: US$1.14 (up from US$0.97 loss in 1Q 2024).

Our free stock report includes 4 warning signs investors should be aware of before investing in Arvinas. Read for free now.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Arvinas Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates.

Looking ahead, revenue is expected to decline by 1.4% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 8.4%.

Performance of the American Pharmaceuticals industry.

The company's shares are down 16% from a week ago.

Risk Analysis

We should say that we've discovered 4 warning signs for Arvinas (2 are potentially serious!) that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.